Deals in brief

The value marked a decrease of 6.5% over the previous month and a rise of 36.5% when compared with the last 12-month average of $584.09m.

The US held a 73.9% share of the global medical devices industry venture financing deal value that totalled $1.08bn in January 2020.

In terms of deal activity, the US recorded 52 deals during January 2020, marking a decrease of 3.7% over the previous month and a drop of 14.8% over the 12-month average.

The combined value of the top five medical devices venture financing deals stood at $395.3m, against the overall value of $797.32m recorded for the month.

The top five medical devices industry deals of January 2020 tracked by GlobalData were:

1) AllianceBernstein Venture Fund, Declaration Partners, Maverick Ventures and SymphonyAI Group’s $150m venture financing of Concerto HealthAI

2) The $80.3m venture financing of Element Biosciences by Fidelity Management & Research, Foresite Capital Management, JS Capital and Venrock Healthcare Capital Partners

3) T. Rowe Price Group and Viking Global Investors’ $75m venture financing of Color Genomics

4) The $45m venture financing of Bigfoot Biomedical by Abbott Laboratories, Cormorant Asset Management, Janus Henderson Group, Quadrant Capital Advisors and Senvest Capital

5) aMoon Partners, Brook Byers, Decheng Capital, Verily Life Sciences, Mayfield Fund, NFX, Pacific eight Ventures and Plum Alley Investments’ venture financing of Mammoth Biosciences for $45m.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

Medical imaging artificial intelligence (AI) start-up Qure.ai has raised $16m in a funding round led by Sequoia India and supported by MassMutual Ventures Southeast Asia.

The money will be used to drive Qure.ai’s geographical expansion, expand its product portfolio and support regulatory clearances.

Qure.ai has trained its AI system on a database of over seven million radiology scans to interpret new images within seconds. The company aims to reduce time to care for patients and make healthcare more accessible in resource-limited settings where an expert interpreter may not be available. The company’s solutions are all CE marked.

Spinal surgery company Viseon has announced the closing of an $18m Series B funding round, co-led by Invus Opportunities, HBM-MedFocus and affiliates of Wexford Capital. The funding will be used to support Viseon’s ongoing product development, worldwide regulatory approvals, clinical evaluations, manufacturing scale-ups and commercialisation efforts.

Viseon is focused on building visualisation and illumination technologies for use in minimally invasive spine surgery (MISS) through its Voyant System. The company’s single-use, disposable MISS access devices are intended to offer an alternative to large, complex surgical microscopes and endoscopes.

California-based medtech company Outset Medical has netted $125m in a Series E equity financing round led by D1 Capital Partners.

Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors and funds advised by T. Rowe Price Associates also contributed towards the financing.

UK-based virtual reality (VR) therapy company Oxford VR has announced the completion of a $12.5m Series A funding round led by Optum Ventures and supported by Luminous Ventures. The capital will fund the firm’s efforts to increase the US presence of its automated VR therapy solution for behavioural health issues.